Skip to content

Tag Archives: Myelofibrosis

Myelofibrosis (Part Two)


In last blog we discussed the definition, the clinical manifestations, the biology, and the first part of the management of myelofibrosis. Let’s review the risk evaluation of myelofibrosis. According the Dynamic International Prognostic Scoring System (DIPSS) the risk grade can be divided into 5 groups. No risk factors – low risk 1 risk factor – […]

Myelofibrosis (Part One)


Definition Myelofibrosis (MF) is a clonal proliferative disease of hematopoietic stem cells, leading to an inappropriate cytokines release, fibrosis of the bone marrow, constitutive mobilization of committed progenitor cells into the peripheral blood and extramedullary hematopoiesis. MF is the most symptomatic and has the worst prognosis among the Philadelphia-chromosome-negative chronic myeloproliferative neoplasms (MPNs). This disease […]

Diagnosis of Myelofibrosis


Current diagnosis of PMF is based on the 2008 World Health Organization (WHO) criteria, which enlist histopathologic, morphologic, clinical, and molecular-cytogenetic variables. The diagnosis of post-PV or post-ET MF is according to IWG-MRT criteria. Table 1 Diagnostic Criteria of Myelofibrosis In all 3 MF variants, typical laboratory features include anemia, peripheral blood leukoerythroblastosis, dacryocytosis, leukocytosis/thrombocytosis, […]